Skip to content

The New Place of LEVETIRACETAM in the Management of Status Epilepticus in Children

The New Place of LEVETIRACETAM in the Management of Status Epilepticus in Children: Multicenter Retrospective Study on 151 Children Over Three Months Old

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06498362
Acronym
LEVET
Enrollment
151
Registered
2024-07-12
Start date
2023-11-16
Completion date
2025-05-16
Last updated
2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy in Children

Keywords

Epilepsy, Epilepsy in Children

Brief summary

Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

* Minor patient aged 3 months to 17 years * 2nd line treatment with LEVETIRACETAM or PHENYTOIN after failure of benzodiazepines * Supported in one of the participating centers during the period from November 1, 2019 to May 31, 2023 * Subject or parents who have not expressed, after information, their opposition to the reuse of their data for the purposes of this research.

Exclusion criteria

* Patient or parents having expressed their opposition to participating in the study.

Design outcomes

Primary

MeasureTime frameDescription
Highlight non-inferiority of LEVETIRACETAM compared to PHENYTOINUp to 2 yearsThe non-inferiority of LEVETIRCETAM in comparison with PHENYTOIN is based on a composite primary endpoint consisting of the total duration of the seizure, the need for another antiepileptic treatment to resolve the seizure or recurrence within 24 hours. following the start of treatment for a new status epilepticus and the total duration of hospitalization. The need for another antiepileptic drug or recurrence is a binary variable with presence (= yes = 1) or absence (= no = 0). The total duration of the crisis is expressed in minutes, and corresponds to the interval between the identification of the event and the objectification of its cessation. The total duration of hospitalization is expressed in days, and corresponds to the duration between the first day of hospitalization (regardless of the location) and the day of discharge (regardless of the department).

Countries

France

Contacts

Primary ContactSarah BAER, MD
sarah.baer@chru-strasbourg.fr33 3 88 12 63 98

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026